Citi analyst Yigal Nochomovitz raised the firm’s price target on Zymeworks (ZYME) to $18 from $16 and keeps a Buy rating on the shares. The company’s Q3 earnings call was “very incrementally informative,” the analyst tells investors in a research note. The firm says that most notably, Zymeworks completed the first $30M tranche of the share repurchase program as of October 31, buying back 2.5M shares at an average price of $11.79.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZYME:
- Zymeworks’ Future Hinges on Developing Key Diagnostic Tests Amidst Regulatory Challenges
- PayPal, Estee Lauder downgraded: Wall Street’s top analyst calls
- Wells downgrades Zymeworks with zanidatamab approval priced in
- Zymeworks downgraded to Equal Weight from Overweight at Wells Fargo
- Zymeworks Reports Q3 Results and Strategic Advances